Investment analysts at StockNews.com started coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Separately, JPMorgan Chase & Co. lowered Clovis Oncology from a “neutral” rating to an “underweight” rating in a research report on Wednesday, November 9th.
Clovis Oncology Stock Up 2.3 %
Shares of CLVS opened at $0.34 on Friday. The business’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.21. Clovis Oncology has a 52-week low of $0.23 and a 52-week high of $3.41. The firm has a market cap of $49.29 million, a price-to-earnings ratio of -0.19 and a beta of 0.41.
Institutional Investors Weigh In On Clovis Oncology
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.